Dissemination (Meeting Coverage)

Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.

A retrospective study on advanced therapy for Inflammatory Bowel Disease (IBD) found minimal new...

A recent study found that long-term use of recombinant zoster vaccine (RZV) was associated with a...

At Maui Derm Hawaii, Joel Gelfand, MD, MSCE, presented as part of “Challenging Cases in Psoriasis.” He published 2 related papers recently, which we summarize.

Bruce Strober, MD, PhD, published a paper recently in JAMA Dermatol focusing on disease burden measurements of meaning to patients with psoriasis.

At Maui Derm Hawaii, Andrew Blauvelt, MD, MBA, presented as part of “Psoriasis Update: 2024.” Here, we summarize a paper he published in this area of study.

At Maui Derm Hawaii, held January 22-26, 2024, Linda Stein-Gold, MD, presented as part of “Challenging Cases in Psoriasis.”

Social determinants of health influenced the achievement of textbook oncological outcomes and overall survival in non-small cell lung cancer.

Lymphovascular invasion is an independent predictor for shorter recurrence-free survival for patients with stage I NSCLC.

Investigators concluded that pre-surgery nutrition support may cut hospital stays for  patients...

Researchers concluded that vedolizumab (vedo) gut-specific targeting spared passive immunity in...

The following is a summary of “Exploring the Relationship Between Patient Symptoms and Provider...

The following is a summary of “Continuous Monitoring of CRP, IL-6, and Calprotectin in...

At the 2024 Winter Clinical Derm Conference, April W. Armstrong, MD, MPH, presented as part of the session “Clinical and Therapeutic Pearls in Psoriasis.”

At the 2024 Winter Clinical Derm Conference, April Armstrong, MD, MPH, and Joseph F. Merola, MD, MMSc, presented “Debate: IL-17 vs IL-23 Blockers for Psoriasis.”

At the 2024 Winter Clinical Dermatology Conference, held January 12-17, 2024 in Honolulu, Mark Lebwohl, MD, presented the session “Late Breakers in Psoriasis.”

Patients reporting increased fatigue have a higher hazard of death compared with those who did not after adjusting for covariates.

Treatment that includes acalabrutinib can improve progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Reckamp co-authored a paper that addresses the need for cautious progression from phase 1 to phase 3 trials for advanced NSCLC, summarized here.

A sandwich treatment model that includes acalabrutinib and rituximab in combination with R-DHAOx chemotherapy shows encouraging results in phase 2 trial.